Clinical trials: Intermediate Risk Prostate Cancer
Prostate Cancer
Spanish Urological Association Registry of Patients on Active Surveillance
Description: Multicentre observational study, not randomized. Ambispective character (retro and prospective). Opened to any member of the Asociación Española de Urología (AEU), public and private medicine.
- Trial name
- NCT02865330
- Testing
- Registry
- Where
- Spain
- Volunteers
- 946 people
- Sponsor
- Fundación Instituto Valenciano de Oncología
Prostate Carcinoma
An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer
The purpose of this study is to evaluate the induction of immune responses against CV9104 administered by conventional intradermal injection or with a needle-free intradermal injection device and to assess the safety and…
- Trial name
- NCT02140138
- Testing
- CV9104, needle free injection device (Tropis®)
- Where
- 3 sites in Germany
- Volunteers
- 35 people
- Sponsor
- CureVac
Prostate Adenocarcinoma
Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer
This is a study to first establish feasibility of the study and then to register the treatment data of adult patients with a diagnosis of intermediate risk of prostate cancer presenting for definitive radiation treatment with…
- Trial name
- NCT01352429
- Testing
- Proton Therapy, IMRT
- Where
- 2 sites in United States
- Volunteers
- 303 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Cancer
Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer
This study will offer men with intermediate risk prostate cancer who are suitable for, and interested in, prostate brachytherapy, the opportunity to be randomized between low dose rate (LDR) brachytherapy using permanent…
- Trial name
- NCT02692105
- Testing
- Low dose rate prostate brachytherapy, High Dose Rate prostate brachytherapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
Vaccination in Prostate Cancer (VANCE)
This is a clinical trial of a new treatment for prostate cancer that is a type of vaccine that could be a new way to treat cancer.
- Trial name
- NCT02390063
- Testing
- ChAdOx1.5T4, MVA.5T4, Cyclophosphamide
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Oxford
Prostate Cancer
Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)
This is a single-site trial for 42 subjects with intermediate risk prostate cancer who undergo Irreversible Electroporation (IRE) followed by Magnetic Resonance guided Radiotherapy MRgRT.
- Trial name
- RTIRE (NCT05345444)
- Testing
- IRE & MRgRT
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Proton Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT01045226
- Testing
- Proton Beam Radiation Therapy, Quality-of-Life assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cancer
Hypofractionated Stereotactic Boost in Prostate Cancer
hypofractionated stereotactic boost radiation (prostate) after normofractionated radiotherapy (prostate + seminal vesicles).
- Trial name
- CKNO-PRO (NCT01596816)
- Testing
- First part of treatment : Conformal irradiation, Fiducials placement, Second part : hypofractionated stereotactic boost
- Where
- 7 sites in France
- Volunteers
- 76 people
- Sponsor
- Centre Oscar Lambret
Prostate Cancer (Adenocarcinoma), Localized Prostate Cancer
68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal Therapy
Focal therapy is a minimally invasive treatment option for some men with localized prostate cancer. Unlike surgery or radiation, focal therapy treats only the area of the prostate containing clinically significant cancer, with…
- Trial name
- PSMA-FT (NCT07747493)
- Testing
- Gallium Ga 68 Gozetotide (68Ga-PSMA-11), Intervention Description: Integrated positron emission tomography/magnetic resonance imaging (PET/MRI) combines molecular imaging with high-resolution anatomical MRI to evaluate intraprostatic lesions
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer
The purpose of this research study is to see if patients' tumor can be identified by 18F-DCFPyL PET/MRI scan. The radioactive study agent, 18FDCFPyL, combined with PET/MRI scan may be able to identify smaller tumors than the…
- Trial name
- NCT04809584
- Testing
- F18-DCFPyL, Gadolinium, Positron emission tomography (PET)/Magnetic Resonance Imaging (MRI) Scan
- Where
- United States
- Sponsor
- Stanford University
Surgical Procedure, Unspecified, Prostate Cancer
Posterior Extra-fascial RARP in Intermediate or High Risk Prostate Cancer
This study was designed as a prospective, multicentre, double-blind, randomised controlled clinical trial. It aims to investigate the feasibility and safety of the posterior approach extrafascial technique and the anterior…
- Trial name
- NCT06434649
- Testing
- Extrafascial robotic assisted radical prostatectomy via posterior approach, Extrafascial robotic assisted radical prostatectomy via anterior approach
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Ning Xu
Neoplasm, Prostate
Androgen Deprivation Therapy, External Beam Radiotherapy and Stereotactic Radiosurgery Boost for Prostate Cancer
For the treatment for intermediate- and high-risk prostate cancer, Cyberknife boost will be used after 4 weeks of intensity modulated radiotherapy to pelvis. The boost doses are 18 Gy and 21 Gy in 3 fractions, respectively.
- Trial name
- ADEBAR (NCT03322020)
- Testing
- Cyberknife boost 18 Gy, Cyberknife boost 21 Gy
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Asan Medical Center
Prostate Cancer
Single Fraction Real-time High-Dose-Rate Brachytherapy in Patients With Low and Intermediate Risk Prostate Cancer
High-dose rate brachytherapy (HDR-BT) is an advanced technology theorized to be more advantageous than LDR-BT and External Beam Radiotherapy (EBRT), to the patient himself, and in terms of resource allocation.
- Trial name
- SINFRA_PROST (NCT02342054)
- Testing
- MRI-TRUS fusion guided Single Frac HDR
- Where
- Spain
- Volunteers
- 49 people
- Sponsor
- Hospital de Cruces
Prostate Cancer
Trial Comparing Radical Radiotherapy to Prostate Only VS Prostate And Pelvic Lymph Nodes in Intermediate And High Risk Prostate Cancer
This phase II randomized controlled study aims to compare the treatment results of intermediate and high risk prostate cancer patients treated with hormonal therapy and radical radiotherapy with or without pelvic lymph nodes in…
- Trial name
- NCT05285319
- Testing
- Prostate Only Radiation, Prostate and Pelvic Lymph Node Radiation
- Where
- Egypt
- Volunteers
- 82 people
- Sponsor
- Cairo University
Prostate Cancer
Transperineal Laser Ablation for Low- and Intermediate Risk Prostate Cancer: a Single Cohort Analysis
The goal of this prospective study is to test the efficacy of Echolaser transperineal focal therapy in patients with low- and intermediate risk prostate cancer. The main question it aims to answer are: 1.
- Trial name
- NCT05584787
- Testing
- Soractelite Echolaser Transperineal focal laser ablation
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- San Carlo di Nancy Hospital
Prostate Cancer
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
The purpose of this study is to compare the effects, good and/or bad of two treatment methods on subjects and their cancer. Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized…
- Trial name
- NCT01492972
- Testing
- Radiation, Androgen Suppression Therapy
- Where
- 4 sites in United States
- Volunteers
- 192 people
- Sponsor
- Proton Collaborative Group
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer
This phase II trial studies how well gallium Ga 68-labeled gastrin-releasing peptide receptor (GRPR) antagonist BAY86-7548 (68Ga-RM2) positron emission tomography (PET)/computed tomography (CT) works in detecting regional nodal…
- Conditions
- Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma, Stage IV Prostate Adenocarcinoma
- Trial name
- NCT03113617
- Testing
- Computed Tomography, Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Andrei Iagaru
Prostate Cancer (Adenocarcinoma)
Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.
Patients with unfavorable intermediate-risk prostate cancer will be randomized between 6 versus 12 months of hormone therapy with radiation therapy.
- Trial name
- PCS-XII (NCT06855589)
- Testing
- 6 months of Eligard, 12 months of Eligard, prostate SBRT or prostate brachytherapy with radiation therapy
- Where
- 5 sites in Canada
- Volunteers
- 400 people
- Sponsor
- Charles LeMoyne Hospital
Prostate Cancer, Low-risk or Favorable Intermediate Risk Prostate Cancer Who Are on an Active Surveillance Regimen
Investigator Initiated Trial to Further Evaluate the Safety and Efficacy of Trans-perineal Focal Laser Ablation of Localized Prostate Cancer Using High Frequency Micro-ultrasound Imaging
Trans-perineal focal laser ablation represents a promising alternative focal therapy option for patients with low-risk or favorable intermediate risk prostate cancer.
- Trial name
- NCT05826470
- Testing
- TRANBERG®|Thermal Therapy System
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Genesis Research LLC
Prostate Cancer
Preoperative Semaglutide Prior to Radical Prostatectomy
In this exploratory, single-arm, nonrandomized trial, the impact of the preoperative utilization of the glucagon-like peptide-1 (GLP-1) receptor agonist (RA) semaglutide prior to radical prostatectomy in participants with…
- Trial name
- NCT07727473
- Testing
- Semaglutide 2.4 mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Banner Health